Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.58 |
| ▸ | STS | P08842 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | CTSE | P14091 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20015307 | 0.93 | ALDH1A1 (0.61) | ALDH1A1GPR119STSBACE1TGFBR1 | |
| SCHEMBL4146238 | 0.87 | GPR119 (0.54) | GPR119FAAH | |
| SCHEMBL1575127 | 0.87 | GPR119 (0.54) | ALDH1A1GPR119MAPTHTTFAAH | |
| SCHEMBL13913655 | 0.86 | KDM4E (0.60) | GPR119STSSMN1; SMN2FAAH | |
| SCHEMBL28169019 | 0.86 | ALDH1A1 (0.62) | ALDH1A1GPR119STSBACE1TGFBR1 | |
| SCHEMBL4147236 | 0.86 | SLC2A1 (0.56) | ALDH1A1GPR119TGFBR1SLC2A1 | |
| SCHEMBL7495311 | 0.86 | GPR119 (0.53) | GPR119FAAH | |
| SCHEMBL7402191 | 0.86 | GPR119 (0.55) | GPR119FAAH | |
| SCHEMBL13279636 | 0.85 | GPR119 (0.52) | GPR119TGFBR1MAPTFAAH | |
| SCHEMBL31752252 | 0.85 | GPR119 (0.60) | GPR119FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | ALDH1A1 1006/4885GPR119 73/4885STS 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.